A phase II, multicenter, open-label study of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer: DESTINY-CRC01 - Siena, S; Di Bartolomeo, M; Raghav, K PS (ASCO20 Virtual Scientific Program)
Abstract 4000. Presented May 29, 2020